Newsroom
Autologous Stem Cell Transplant Can Improve Survival in MM Patients
Newly diagnosed multiple myeloma patients undergoing ASCT showed a significant improvement in survival.
FDA Warns of Intoxication Following IV Docetaxal
The US FDA has warned that intravenous administration docetaxal formulations contain alcohol and may cause intoxication among patients. A product label revision is being made.
Legislation Would Factor Patient Finances into Readmission Penalities
The Senate introduced legislation this week that would require Medicare to consider patients' finances when deciding whether to punish a hospital for readmission numbers.
VA Governor to Bypass Lawmakers, Expand Medicaid
Virginia Gov. Terry McAuliffe vowed Friday to bypass the General Assembly and expand Medicaid eligibility for about 400,000 low-income residents on his own.
By 2020, Most States Will Be on the Federal Exchange
I’ll say it: I think most states, if not all, will be on the Federal exchange by the end of the decade.
Newfound Risk That Providers, Payers, and Patients Are Navigating With the Implementation of the Affordable Care Act
A panel asks: “Due to the ACA, who is now presenting with cancer? Who is walking through the door and is there a difference between patients since the ACA implementation?”
Consumer Group Urges Hospitals To Stop Promoting Questionable Screenings
Consumer advocacy group Public Citizen on Thursday called on 20 hospital systems to stop partnering with companies that offer low-cost screenings for heart disease and stroke risk, saying the promotions are “unethical” and the exams are more likely to do harm than good.
Anti-CD20 Antibody Improves Lenalidomide Performance in CLL
From 20 months to upto 5 years, blocking CD20 significantly improved OS in CLL patients.
Need Better Representation of Women and Minorities in Trials: Democrats
Twenty-two Democratic lawmakers have asked the National Institutes of Health to publicly disclose demographic data for all clinical trials posted on ClinicalTrials.gov.
As Sequencing Moves into Clinical Use, Insurers Balk
Once strictly the domain of research labs, gene-sequencing tests increasingly are being used to help understand the genetic causes of rare disease, putting insurance companies in the position of deciding whether to pay the $5,000 to $17,000 for the tests.
ACO Initiatives Test Pharma's Traditional Sales Model
The US healthcare system’s shift from volume- to value-based reimbursement for treatment in order to lower costs and improve patient care is disrupting healthcare business models. The high-profile government–led accountable care organizations (ACOs), which put financial pressure on payers and providers to share responsibility for meeting quality and cost goals, is no exception.
AJMC Sets Infectious Disease Meeting for Atlanta
The American Journal of Managed Care will host a two-day event September 25-26, 2014, to take on some of healthcare’s biggest challenges: Treatments that cure hepatitis C are making news but upending balance sheets. A recent recommendation seeks preventive therapy to stop new cases of HIV. Hospitals and public health officials are grappling with how to prevent the spread of MERS. Only AJMC will bring payers, clinicians, policy leaders, and pharmaceutical representatives together to share ideas.
Alternate Indications: Heparin Derivative in Treating Neuroblastoma?
The derivative slowed tumor growth, shrunk tumors, and extended the life of the mice.
BRCA2 Associated With Risk of Lung Cancer Among Smokers
BRCA2 mutation, a genetic risk factor for breast and ovarian cancer, has been implicated in squamous cell lung cancer among cigarette smokers.
HHS Will Enforce Disputed Rule Limiting Orphan Exclusion from 340B Drug Discounts
HHS is moving forward with its plan to allow certain hospitals to receive discounts on orphan drugs when they are used for non-orphan conditions despite a court ruling that said the agency did not have the authority to do so.
3D Mammograms More Powerful than 2D
In community-based radiology practice, mammography screening with 3D digital breast tomosynthesis (DBT) yielded lower recall rates, an increased overall cancer detection rate, and an increased detection rate for invasive cancer compared with 2D digital mammography (DM).
Insurer Begins Huge Palliative Care Program
“Person-centered care” is the buzz phrase floating around the health care industry, and a Pacific Northwest-based giant insurer thinks it has hit the mark with a new palliative care program coming this summer.
Former ONC Chief Mostashari Heads ACO Startup
Dr. Farzad Mostashari, former head of the Office of the National Coordinator for Health Information Technology, is starting a new firm, Aledade, to help independent primary-care physicians form accountable care organizations.
Pfizer Steps into the CAR-T Immunotherapy Field With Cellectis Deal
Pfizer's deal with the French company will ensure a market share in the promising immunooncology field.
Fast Track Status for the Oncolytic Virus Treatment Being Developed by DNAtrix
The oncolytic adenovirus vaccine, DNX-2401, being developed by DNAtrix to treat recurrent glioblastoma, has received a fast-track status by the FDA.
Personalized Mouse TumorGrafts to Evaluate Treatment Benefits
Icahn School of Medicine at Mount Sinai and Champions Oncology have initiated a study evaluating TumorGrafts' ability to predict treatment benefit in patients with triple-negative breast cancer. A side-by-side genomic analysis of patients' tumor and TumorGraft mouse avatars, before and after treatment, will also be conducted.
Movement Toward Exchanges Faster than Anticipated
Two measures of the evolving health insurance market show that change is happening more quickly than anticipated.
Low-dose Dexamethasone with Pomalidomide Significantly Improves OS in MM
Low-dose dexamethasone with pomalidomide improved overall survival to 12.7 months, compared to 5.7 months with high-dose dexamethasone.
Lung-MAP Study Kicked-off at Multiple Hospitals in the United States
A bold new way to test cancer drugs started Monday in hundreds of hospitals around the United States.
Proteomics to Confirm Treatment Benefit in NSCLC
A proteomic test can predict outcome with chemotherapy versus erlotinib in NSCLC patients.